These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 38137380)
1. Targeting CD24 in Cancer Immunotherapy. Chen W; Hu Z; Guo Z Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137380 [TBL] [Abstract][Full Text] [Related]
2. CD24: A Novel Target for Cancer Immunotherapy. Panagiotou E; Syrigos NK; Charpidou A; Kotteas E; Vathiotis IA J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013184 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint CD24 function on tumor and immunotherapy. Huang S; Zhang X; Wei Y; Xiao Y Front Immunol; 2024; 15():1367959. PubMed ID: 38487533 [TBL] [Abstract][Full Text] [Related]
4. Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies. Hazra R; Chattopadhyay S; Mallick A; Gayen S; Roy S Immunology; 2024 Nov; 173(3):442-469. PubMed ID: 39129256 [TBL] [Abstract][Full Text] [Related]
5. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998 [TBL] [Abstract][Full Text] [Related]
6. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners. Söhngen C; Thomas DJ; Skowron MA; Bremmer F; Eckstein M; Stefanski A; Driessen MD; Wakileh GA; Stühler K; Altevogt P; Theodorescu D; Klapdor R; Schambach A; Nettersheim D FEBS J; 2023 Oct; 290(20):4864-4876. PubMed ID: 37254618 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444 [TBL] [Abstract][Full Text] [Related]
8. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026 [TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099 [TBL] [Abstract][Full Text] [Related]
10. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy. Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749 [TBL] [Abstract][Full Text] [Related]
12. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Abbott RC; Cross RS; Jenkins MR Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597 [TBL] [Abstract][Full Text] [Related]
13. IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy. Li S; Chen D; Guo H; Yang Y; Liu D; Yang C; Bai X; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Song Y; Jiang Z; Zhang R; Yu J; Tian W Antib Ther; 2023 Oct; 6(4):240-252. PubMed ID: 37846296 [TBL] [Abstract][Full Text] [Related]
14. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. Moon SY; Han M; Ryu G; Shin SA; Lee JH; Lee CS Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894750 [TBL] [Abstract][Full Text] [Related]
15. Targeting CD24 as a novel immunotherapy for solid cancers. Yang Y; Zhu G; Yang L; Yang Y Cell Commun Signal; 2023 Nov; 21(1):312. PubMed ID: 37919766 [TBL] [Abstract][Full Text] [Related]
16. CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Chan LY; Dass SA; Tye GJ; Imran SAM; Wan Kamarul Zaman WS; Nordin F Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453554 [TBL] [Abstract][Full Text] [Related]
17. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211 [TBL] [Abstract][Full Text] [Related]
18. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. Chung C Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103 [TBL] [Abstract][Full Text] [Related]
19. The biological roles of CD24 in ovarian cancer: old story, but new tales. Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K Front Immunol; 2023; 14():1183285. PubMed ID: 37359556 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]